DDrare: Database of Drug Development for Rare Diseases

118. 脊髄髄膜瘤
［臨床試験数：9，薬物数：15（DrugBank：7），標的遺伝子数：8，標的パスウェイ数：11］

Searched query = "Myelomeningocele", "Myeloschisis", "Myelocele", "Myelocystocele", "Syringomyelocele"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Atosiban; Botulinum A toxin; Device: In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique; Device: In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique; Device: Minimally invasive fetoscopic repair of MMC; Device: Omnidirectional accelerometer monitor (3x3 cm and 16 g, Actical®, Philips Respironics); MMC; MONITOR; Placental Mesenchymal Stem Cells; Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix; Procedure: Fetal surgery for MMC repair; Procedure: endoscopic repair of myelomeningocele before 26 SA; SA; Terbutaline; Uterine

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04468568 (ClinicalTrials.gov)	January 8, 2017	1/3/2020	In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline	Assessment of Maternal Blood Gas Changes When Using Atosiban and Terbutaline as Tocolytic Agents, During in Utero Repair of Myelomeningocele	Myelomeningocele;Terbutaline Adverse Reaction;Pregnancy; Malformation Central Nervous System	Drug: Atosiban;Drug: Terbutaline	University of Sao Paulo General Hospital	NULL	Recruiting	18 Years	40 Years	Female	28	N/A	Brazil

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04468568
(ClinicalTrials.gov)

January 8, 2017

1/3/2020

In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline

Assessment of Maternal Blood Gas Changes When Using Atosiban and Terbutaline as Tocolytic Agents, During in Utero Repair of Myelomeningocele

Myelomeningocele;Terbutaline Adverse Reaction;Pregnancy; Malformation Central Nervous System

Drug: Atosiban;Drug: Terbutaline

University of Sao Paulo General Hospital

NULL

Recruiting

18 Years

40 Years

Female

N/A

Brazil